RxDoctor Payments Data

Ankit Patel, MD

Interventional Cardiology · Braselton, GANPI 1801089842

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (37.9%), food and beverage and travel and lodging — rather than concentrated in one kind of arrangement. 38 manufacturers reported payments, led by Shockwave Medical, Inc at 39.7% of the total. Reporting peaked in 2023 at $8,055 and has fallen 91.3% since, to $699 in 2025.

$17,433in general payments, 2019–2025

Across 185 payments — averaging $94.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Shockwave Medical, Inc$7K
  • Abbott$2K
  • Medtronic$2K
  • Cardiovascular Systems Inc.$2K
  • Abiomed$545
  • Cordis US CORP.$512
  • plus $4K from 32 others
$80,562in research payments, 2019–2025

Across 19 payments — averaging $4240.09 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Shockwave Medical, Inc$58K
  • Abbott$23K

What the payments were for

  • Consulting fees$8505%
  • Speaking & faculty fees$6,60038%
  • Travel & lodging$3,55820%
  • Food & beverage$6,40837%
  • Education$170%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$17,433 in reported general payments places this provider in the 70th percentile of 218 interventional cardiology providers in Georgia.

See all interventional cardiology providers in Georgia

Medicare billing

Part B allowed, 2024
$227,549
Medicare patients
896
Services billed
2,861

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
EliquisApixaban221$221,337
XareltoRivaroxaban54$72,958
EntrestoSacubitril/Valsartan33$55,093
BrilintaTicagrelor49$46,549
FarxigaDapagliflozin Propanediol42$33,228
Repatha SureclickEvolocumab25$18,812
JardianceEmpagliflozin12$17,681
Metoprolol Succinate354$3,792
Atorvastatin Calcium422$3,673
ClopidogrelClopidogrel Bisulfate302$3,418
Ranolazine ErRanolazine24$3,158
Diltiazem 12hr ErDiltiazem Hcl14$3,070
Carvedilol315$2,135
Rosuvastatin Calcium116$1,706
Ezetimibe76$1,599

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
PfizerEliquis$169$221,337221 claims
AstraZenecaBrilinta, Farxiga$174$79,77891 claims
Johnson & JohnsonXarelto$157$72,95854 claims
NovartisEntresto$285$55,09333 claims
Boehringer IngelheimJardiance$38$17,68112 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 70th percentile of 218 interventional cardiology providers in Georgia.

Other interventional cardiology in Braselton

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →